Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation.

Blood Advances
Johannes Frasez SoerensenAnne Stidsholt Roug

Abstract

Therapy-related myeloid neoplasms (tMN) develop after exposure to cytotoxic and radiation therapy, and due to their adverse prognosis, it is of paramount interest to identify patients at high risk. The presence of clonal hematopoiesis has been shown to increase the risk of developing tMN. The value of analyzing hematopoietic stem cells harvested at leukapheresis before autologous stem cell transplantation (ASCT) with next-generation sequencing and immunophenotyping represents potentially informative parameters that have yet to be discovered. We performed a nested case-control study to elucidate the association between clonal hematopoiesis, mobilization potential, and aberrant immunophenotype in leukapheresis products with the development of tMN after ASCT. A total of 36 patients with nonmyeloid disease who were diagnosed with tMN after treatment with ASCT were included as case subjects. Case subjects were identified from a cohort of 1130 patients treated with ASCT and matched with 36 control subjects who did not develop tMN after ASCT. Case subjects were significantly poorer mobilizers of CD34+ cells at leukapheresis (P = .016), indicating that these patients possess inferior bone marrow function. Both clonal hematopoiesis (odd...Continue Reading

References

Mar 23, 2011·Aging Cell·Klaudia KurandaMichele Goodhardt
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Nov 27, 2014·The New England Journal of Medicine·Giulio GenoveseSteven A McCarroll
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Aug 19, 2016·Nature·Monkol LekUNKNOWN Exome Aggregation Consortium
Aug 23, 2016·Nature Communications·Andrew L YoungTodd E Druley
Jan 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J GibsonBenjamin L Ebert
Feb 6, 2017·Blood·Daniel Thomas, Ravindra Majeti
Jun 22, 2017·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Mar 31, 2018·The New England Journal of Medicine·Mojca Jongen-LavrencicPeter J M Valk
Apr 19, 2018·Cancer Genetics·Takahiro NishiyamaHitoshi Kiyoi
May 26, 2018·Leukemia·Cassandra M HirschJaroslaw P Maciejewski
Jul 11, 2018·Nature·Sagi AbelsonLiran I Shlush
Jul 11, 2018·Nature Medicine·Pinkal DesaiDuane C Hassane
Jul 27, 2018·Leukemia Research·Guru Subramanian Guru MurthyEhab Atallah
Sep 12, 2018·Annals of Hematology·Helena ClaerhoutNancy Boeckx
Nov 6, 2018·Cell Stem Cell·Joanne I HsuMargaret A Goodell
Apr 21, 2019·Haematologica·Andrew L YoungTodd E Druley

❮ Previous
Next ❯

Citations

Jan 5, 2021·Current Opinion in Hematology·C Matthias WilkSteffen Boettcher
Feb 20, 2021·British Journal of Haematology·Robert P Hasserjian
Mar 10, 2021·Pathology·Danielle Hammond, Sanam Loghavi
Jul 4, 2021·Leukemia·Malte von BoninMartin Bornhäuser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Christopher J GibsonBenjamin L Ebert
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Margaret M ShowelRichard J Jones
Current Opinion in Hematology
Virginia M Klimek, Nancy J Tray
© 2021 Meta ULC. All rights reserved